MRICD pioneered many of the techniques that have become standards in the life-science studies of chemical agents.
MRICD’s demonstrated skill in developing innovative solutions to complex technical problems has resulted in our ability to move from basic research findings to applications for medical treatment. All currently available medical countermeasures against chemical warfare agents, to include cholinolytic antidotes, oxime enzyme reactivators, carbamate pretreatments, benzodiazepine anticonvulsants, reactive skin decontaminants and topical skin protectants, were either fully developed at the MRICD or had most preclinical efficacy testing done at the MRICD prior to FDA licensure.
MRICD is strengthening the defense of our nation by rendering chemical and biochemical threats medically harmless.
A History of Providing Medical Protection for the Warfighter
1980's
MARK I Nerve Agent Antidote Kit
FDA approval and fielding of MARK I
1990's
TestMate® Cholinesterase Kit
Measures blood enzymes erythrocyte AChE and/or plasma cholinesterase, providing detection of nerve agent exposure in less than 4 minutes
Convulsant Antidote Nerve Agent (CANA)
Fielding of diazepam in the CANA autoinjector
2000's
Reactive Skin Decontamination Lotion
Conducted decisive studies on the efficacy of RSDL
ATNAA
FDA approval of Antidote Treatment Nerve Agent Autoinjector
Pyridostigmine
FDA approval of pyridostigmine bromide under the "Animal Efficacy Rule" to increase survival after soman exposure
SERPACWA
FDA approval of Skin Exposure Reduction Paste Against Chemical Warfare Agents
MRICD's Solutions for CBRNE Threats
2000's
Midazolam
AAS (Advanced Anticonvulsant System)
Plasma-Derived BChE and Recombinant BChE
First ever nerve agent prophylactic that prevents incapacitation and death from exposure to a broad spectrum of nerve agents
2010's
PBA/FGA Treatment Guidelines
Provided subject matter expertise in guideline development
Nerve Agent Treatment Systems (new reactivators and adjunct treatments)
Improved Nerve Agent Treatment System: Centrally Acting (INATS -CA)
Reactive Nerve Agent Treatment System (RNATS)
ChemDXAn ultra-portable, low complexity in vitro diagnostics system to provide indication of CWA exposure on the battlefield
Naloxone Autoinjector
Critical efficacy studies
